India’s Diabetes and Weight Loss Drug Market Heats Up with Generic Semaglutide Launch
Hyderabad-based Dr. Reddy’s Laboratories (DRL) has officially entered India’s growing glucagon-like peptide-1 (GLP-1) market with the launch of Obeda, a generic version of semaglutide, designed for managing Type 2 diabetes. This launch follows the expiration of the original semaglutide patent and signals a potential shift in affordability and accessibility for patients.
A 62% Price Drop: Making GLP-1 Therapy More Accessible
Obeda is priced at ₹4,200 per month for both the 2mg and 4mg strengths, representing a significant 62% reduction compared to the highest dosage of the innovator drug, Ozempic, marketed by Novo Nordisk. This price difference is expected to dramatically increase access to GLP-1 receptor agonist therapy for the estimated 101 million people in India living with diabetes and the 136 million in the prediabetic segment.
Beyond Diabetes: The Rise of GLP-1s for Weight Management
GLP-1 agonists like semaglutide work by regulating blood sugar, increasing feelings of fullness, and slowing down stomach emptying. While initially developed for diabetes, these drugs have gained prominence for their weight loss benefits. DRL anticipates receiving regulatory approval to market a semaglutide generic specifically for weight management in the coming months.
Rapid Market Growth and Competition
The Indian injectable GLP-1 agonist segment has already experienced substantial growth, with sales increasing by 177% in the last year – from ₹571 crore in February 2025 to ₹1,446 crore in February 2026. The market is poised for further expansion, with over 50 generic semaglutide options expected to turn into available in India within the next month. Sun Pharma and Glenmark have also launched their own generic versions.
DRL’s Expansion Strategy: India and Beyond
DRL plans to manufacture and sell 12 million injectable Semaglutide pens in the first year. The company aims to become a top five player in the Indian semaglutide market. DRL intends to introduce generic semaglutide in several countries, maintaining a “One Product, One Quality” standard across all markets. The company is also exploring partnerships with other drugmakers for both production and distribution.
Navigating Regulatory Hurdles: The Canadian Experience
DRL’s international expansion isn’t without challenges. The launch of generic semaglutide in Canada was temporarily paused due to a Notice of Non-Compliance (NON) from Health Canada regarding its Abbreviated New Drug Submission (ANDS). DRL is actively addressing the regulator’s concerns and working towards a resolution.
In-House Manufacturing for Supply Chain Control
DRL has invested in developing and manufacturing both the active pharmaceutical ingredient (API) and the formulation for Obeda in-house. This strategy provides greater control over the supply chain and ensures consistent product quality.
What Does This Mean for Patients?
The availability of affordable generic semaglutide is a game-changer for individuals with Type 2 diabetes and those seeking weight loss solutions in India. The lower cost will make the medication accessible to a wider population, potentially improving health outcomes and reducing the burden of these chronic conditions.
Did you grasp?
India has the second-highest population living with type 2 diabetes after China, alongside rapidly increasing obesity rates, according to the World Health Organisation (WHO).
FAQ
Q: What is semaglutide?
A: Semaglutide is a medication used to treat Type 2 diabetes and, increasingly, for weight loss. It belongs to a class of drugs called GLP-1 receptor agonists.
Q: How much does Obeda cost?
A: Obeda is priced at ₹4,200 per month for both the 2mg and 4mg strengths.
Q: What are the benefits of GLP-1 agonists?
A: GLP-1 agonists help regulate blood sugar, increase fullness, and slow stomach emptying, leading to improved glucose control and potential weight loss.
Q: Is Obeda only for diabetes?
A: Currently, Obeda is approved for Type 2 diabetes management. DRL is seeking approval to market it for weight management as well.
Q: Where will Dr. Reddy’s sell generic semaglutide?
A: Initially in India, with plans to expand to multiple countries, including Canada, subject to regulatory approvals.
Pro Tip: Discuss with your healthcare provider whether GLP-1 agonists are the right treatment option for you, considering your individual health needs and medical history.
Want to learn more about managing diabetes and weight loss? Explore our other articles on healthy living.
